VD-CAG AML Study: 11-Gene Prognostic Signature and Multi-Omics Data

15 non-M3 acute myeloid leukemia patients were profiled with RNA sequencing and proteomics before and after VD-CAG induction therapy. The study identified a validated 11-gene prognostic signature (TLN1, ARL15, PDZD2, ACER2, IGF2BP3, TMEM200A, DOCK1, SYTL4, CPNE8, FNDC3B, MANBA) with strong predictive performance in external cohorts. The dataset was authored by Jirui Tang and last updated on 2026-05-19.

Use Cases

• Validate the 11-gene prognostic signature based on gene expression data mentioned in the description
• Analyze molecular alterations associated with VD-CAG treatment based on pre- and post-treatment multi-omics profiles
• Investigate pathways like MAPK signaling and cell adhesion enriched in treatment response
• Correlate proteomic changes, such as FNDC3B downregulation, with transcriptomic data

Strengths

• Includes multi-omics data from 15 patient samples, with 10 pairs for RNA-seq and 5 pairs for proteomics
• Prognostic signature was validated in an external cohort (Beat AML) with a reported 3-year AUC of 0.83
• Dataset is openly licensed under CC-BY-4.0

Limitations

• Row count is unknown, which may limit suitability assessment
• Column-level documentation is absent; field semantics must be inferred after download
• The dataset is small at 216.5 KB, indicating limited scope

Provenance

Source

figshare

Collection Method

Integrative multi-omics profiling of bone marrow samples from a clinical study, with external validation using TCGA-LAML and Beat AML cohorts.

Freshness

Last updated 2026-05-19 04:22:46; freshness should be verified